Cancer

RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer

SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products…

9 months ago

Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland

Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…

10 months ago

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J.,…

10 months ago

Immunocore announces upcoming presentation and posters at ESMO 2023

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic…

10 months ago

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company…

10 months ago

Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 November 2023

PRESS RELEASEREGULATED INFORMATION06 October 2023, 07:00 am CEST   Ghent, Belgium – 06 October 2023 – Sequana Medical NV (Euronext…

10 months ago

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three…

10 months ago

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused…

10 months ago

Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials

VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO);(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to…

10 months ago